Treatment liquid for exclusion of steroid included in cyclodextrin

Patent metadata

Field	Value
Publication number	US-2020355705-A1
Application number	US-201816765018-A
Country	US
Kind code	A1
Filing date	Nov 16, 2018
Priority date	Nov 17, 2017
Publication date	Nov 12, 2020
Grant date	—

Abstract

In a method for immunologically quantifying a steroid, it is possible to exclude a steroid from cyclodextrin when a standard solution containing the steroid included in cyclodextrin is treated with a surfactant, which thereby suppresses the deviation in behavior of the antigen-antibody reaction between the specimen (test sample) and the standard solution, and then significantly improves the accuracy of steroid quantification.

First claim

1 . A treatment liquid for use in exclusion of a steroid included in cyclodextrin, comprising a surfactant as an active ingredient.

2 . The treatment liquid according to claim 1 , wherein the surfactant has an acyl group or alkyl group having 8 carbon atoms, or has a steroid skeleton.

3 . The treatment liquid according to claim 2 , wherein the surfactant is at least one selected from the group consisting of the following (a) to (e):
(a) surfactants having octanoyl groups and glucamine groups; (b) surfactants having octyl groups and polyoxyethylene groups; (c) surfactants having octyl groups, sulfonate groups, and ammonium groups; (d) surfactants having steroid skeletons, sulfonate groups, and ammonium groups; and (e) surfactants having steroid skeletons and carboxylate groups.

4 . The treatment liquid according to claim 3 , wherein the surfactant is at least one selected from the group consisting of N-octanoyl-N-methylglucamine, poly(oxyethylene)octylphenyl ether, N-octyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, and sodium deoxycholate.

5 . The treatment liquid according to claim 1 , wherein the cyclodextrin is at least one selected from the group consisting of β-cyclodextrin, hydroxypropyl β-cyclodextrin, and γ-cyclodextrin.

6 . The treatment liquid according to claim 1 , wherein the steroid is at least one selected from the group consisting of aldosterone, progesterone, 25-hydroxyvitamin D, and estradiol.

7 . The treatment liquid according to claim 1 for use in exclusion of a steroid included in the cyclodextrin in a standard solution for steroid immunological quantification containing the steroid and the cyclodextrin.

8 . A method for immunologically quantifying a steroid, comprising:
reacting an anti-steroid antibody with each of a test sample and a standard solution containing a steroid and cyclodextrin; measuring signal intensities of antigen-antibody reactions in the test sample and the standard solution; and comparing the signal intensity in the test sample with the signal intensity in the standard solution, wherein the treatment liquid according to claim 7 is added to a reaction system of the antigen-antibody reaction in the standard solution.

9 . A kit for immunologically quantifying a steroid, comprising at least the following (a) to (c):
(a) an anti-steroid antibody; (b) a standard solution containing a steroid and cyclodextrin; and (c) the treatment liquid according to claim 7 .

10 . The treatment liquid according to claim 2 , wherein the cyclodextrin is at least one selected from the group consisting of β-cyclodextrin, hydroxypropyl β-cyclodextrin, and γ-cyclodextrin.

11 . The treatment liquid according to claim 2 , wherein the steroid is at least one selected from the group consisting of aldosterone, progesterone, 25-hydroxyvitamin D, and estradiol.

12 . The treatment liquid according to claim 2 for use in exclusion of a steroid included in the cyclodextrin in a standard solution for steroid immunological quantification containing the steroid and the cyclodextrin.

13 . The method for immunologically quantifying a steroid according to claim 8 , wherein the surfactant comprised in the treatment liquid has an acyl group or alkyl group having 8 carbon atoms, or has a steroid skeleton.

14 . The kit for immunologically quantifying a steroid according to claim 9 , wherein the surfactant comprised in the treatment liquid has an acyl group or alkyl group having 8 carbon atoms, or has a steroid skeleton.

15 . The treatment liquid according to claim 3 , wherein the cyclodextrin is at least one selected from the group consisting of β-cyclodextrin, hydroxypropyl β-cyclodextrin, and γ-cyclodextrin.

16 . The treatment liquid according to claim 3 , wherein the steroid is at least one selected from the group consisting of aldosterone, progesterone, 25-hydroxyvitamin D, and estradiol.

17 . The treatment liquid according to claim 3 for use in exclusion of a steroid included in the cyclodextrin in a standard solution for steroid immunological quantification containing the steroid and the cyclodextrin.

18 . The method for immunologically quantifying a steroid according to claim 8 , wherein the surfactant comprised in the treatment liquid is at least one selected from the group consisting of the following (a) to (e):
(a) surfactants having octanoyl groups and glucamine groups; (b) surfactants having octyl groups and polyoxyethylene groups; (c) surfactants having octyl groups, sulfonate groups, and ammonium groups; (d) surfactants having steroid skeletons, sulfonate groups, and ammonium groups; and (e) surfactants having steroid skeletons and carboxylate groups.

19 . The kit for immunologically quantifying a steroid according to claim 9 , wherein the surfactant comprised in the treatment liquid is at least one selected from the group consisting of the following (a) to (e):
(a) surfactants having octanoyl groups and glucamine groups; (b) surfactants having octyl groups and polyoxyethylene groups; (c) surfactants having octyl groups, sulfonate groups, and ammonium groups; (d) surfactants having steroid skeletons, sulfonate groups, and ammonium groups; and (e) surfactants having steroid skeletons and carboxylate groups.

20 . The treatment liquid according to claim 4 , wherein the cyclodextrin is at least one selected from the group consisting of β-cyclodextrin, hydroxypropyl β-cyclodextrin, and γ-cyclodextrin.

Assignees

• Fujirebio Kk

Inventors

• Yoshimi Tatsunari
• TERUYAMA Kyoko

Classifications

• G01N2400/18

  Cyclodextrin · CPC title

• G01N2496/25

  containing added polymers to stabilise biological material against degradation or maintain viscosity or density, e.g. gelatin, polyacrylamides or polyvinyl alcohol · CPC title

• G01N33/743 Primary

  Steroid hormones · CPC title

• G01N33/5306 Primary

  Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding · CPC title

• G01N33/5436

  with ligand physically entrapped within the solid phase (liposomes G01N33/5432; immunological test elements G01N33/54386) · CPC title